<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; EORTC</title>
	<atom:link href="http://oralcancernews.org/wp/tag/eortc/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:09:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes</title>
		<link>http://oralcancernews.org/wp/high-rate-of-severe-radiation-dermatitis-during-radiation-therapy-with-concurrent-cetuximab-in-head-and-neck-cancer-results-of-a-survey-in-eortc-institutes/</link>
		<comments>http://oralcancernews.org/wp/high-rate-of-severe-radiation-dermatitis-during-radiation-therapy-with-concurrent-cetuximab-in-head-and-neck-cancer-results-of-a-survey-in-eortc-institutes/#comments</comments>
		<pubDate>Sun, 16 Nov 2008 18:29:22 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EORTC]]></category>
		<category><![CDATA[radiation dermatitis]]></category>
		<category><![CDATA[radiotherapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=732</guid>
		<description><![CDATA[Source: Radiother Oncol, October 30, 2008 Author: Christian Giro et al. Objective: Examination of the rate of grade III or grade IV radiation dermatitis during treatment of head and neck cancer (HNC) with radiotherapy (RT) and concurrent cetuximab in EORTC centres. Materials and Method: A questionnaire was sent to all members of the EORTC Radiation [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/high-rate-of-severe-radiation-dermatitis-during-radiation-therapy-with-concurrent-cetuximab-in-head-and-neck-cancer-results-of-a-survey-in-eortc-institutes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

